In silico study to analyse the disassembly of quercetin-targeted dendrimers potentially leishmanicide

References

• Amato VS, Tuon FF, Siqueira AM, Nicodermo AC, Amato Neto V. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007;77:266–274.
   PubMed Web of Science ®Google Scholar
• Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873–882.
   PubMed Web of Science ®Google Scholar
• González U, Pinart M, Reveiz L, Pardo MR, Tweed J, Macaya A, Alvar J. Designing and reporting clinical trials on treatments for cutaneous leishmaniasis. Clin Infect Dis. 2010;51:409–419.
   PubMed Web of Science ®Google Scholar
• Neuber H. Leishmaniasis. J Dtsch Dermatol Ges. 2008;6:6754–6765.
   Google Scholar
• World Health Organization. Report of a meeting of the WHO expert committee on the control of leishmaniasis. WHO Tech Rep Ser. 2011;949:1–46.
   Google Scholar
• Chung MC, Ferreira EI, Santos JL, Giarolla J, Rando DG, Almeida AE, Bosquesi PL, Menegon RN, Blau L. Prodrugs for the treatment of neglected diseases. Molecules. 2008;13:616–677.
   Web of Science ®Google Scholar
• Pietro AD, Conseil G, Victoria JMP, Dayan G, Cortay HB, Trompier D, Steinfels E, Jault JM, Wet H, Maitrejean M, Comte G, Boumendjel A, Mariotte AM, Dumontet C, Mcintosh DB, Goffeau A, Castanys S, Gamarro F, Barron D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci. 2002;59:307–322.
   PubMed Web of Science ®Google Scholar
• Tasdemir D, Kaiser M, Brun R, Yardley V, Schmidt TJ, Tosun F, Rüedi P. Antitrypanosomal and antileishmanial activities of flavonoids and their analogues: in vitro, in vivo, structure–activity relationship, and quantitative structure-activity relationship studies. Antimicrob Agents Chemother. 2006;50:1352–1364.
   PubMed Web of Science ®Google Scholar
• Chung MC, Silva AT, Castro LF, Güido RVC, Nassute JC, Ferreira EI. Prodrug design and advanced drug delivery systems. Braz. J. Pharm. Sci. 2005;41:155–179.
   Google Scholar
• Silva ATA, Castro LF, Güido RVC, Chung MC, Ferreira EI. Advances in prodrug design. Mini Rev Med Chem. 2005;5:893–914.
   PubMed Web of Science ®Google Scholar
• Ettmayer P, Amidon GL, Clement B, Testa B. Lesson learned from marketed and investigational prodrugs. J Med Chem. 2004;47:2393–2404.
   PubMed Web of Science ®Google Scholar
• Testa B. Prodrugs research: fertile or futile? Biochem Pharmacol. 2004;68:2097–2106.
   PubMed Web of Science ®Google Scholar
• Najlah M, Freeman S, Attwood D, D'Emanuele A. Synthesis, characterization and stability of dendrimer prodrugs. Int J Pharm. 2006;308:175–182.
   PubMed Web of Science ®Google Scholar
• Najlah M, Freeman S, Attwood D, D'Emanuele A. In vitro evaluation of dendrimer prodrugs for oral drug delivery. Int J Pharm. 2007;336:183–190.
   PubMed Web of Science ®Google Scholar
• Klajnert B, Bryszewska M. Dendrimers: properties and applications. Acta Biochim Pol. 2001;48:199–208.
   PubMed Web of Science ®Google Scholar
• D'Emanuele A, Attwood DD. Dendrimer–drug interaction. Adv Drug Deliv Rev. 2005;57:2147–2162.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Xu Z, Ma M, Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. Pharm Sci. 2008;97:123–143.
   PubMed Web of Science ®Google Scholar
• Ferreira EI, Giarolla J, EI Patent 018070068714; 2007 (under analysis).
   Google Scholar
• Giarolla J, Rando DG, Pasqualoto KFM, Zaim MH, Ferreira EI. Molecular modeling as a promising tool to study dendrimer prodrugs delivery. J Mol Struct THEOCHEM. 2010;939:133–138.
   Web of Science ®Google Scholar
• Giarolla J, Pasqualoto KFM, Rando DG, Zaim MH, Ferreira EI. Molecular modeling study on the disassembly of dendrimers designed as potential antichagasic and antileishmanial prodrugs. J Mol Model. 2012;18:2257–2269.
   PubMed Web of Science ®Google Scholar
• Santos SS, Giarolla J, Pasqualoto KFM, Ferreira EI. Molecular modeling as a tool for studying the disassembly of potentially leishmanicide-targeted dendrimer. Mol Simulat. 2013;39:860–867.
   Web of Science ®Google Scholar
• Drew ME, Langford CK, Klamo EM, Russell DG, Kavanaugh MP, Landfear SM. Functional expression of a myo-inositol/H+ Symporter from Leishmania donovani. Mol Cell Biol. 1995;15:5508–5515.
   PubMed Web of Science ®Google Scholar
• Paila YD, Saha B, Charropadhyay A. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages. Biochem Biophys Res Commun. 2010;399:429–433.
   PubMed Web of Science ®Google Scholar
• Hypercube, Inc. Hypoerchem program for Windows, 7V. Gainesville (FL): Hypercube, Inc.; 2002.
   Google Scholar
• Allinger NL. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc. 1977;99:8127–8134.
   Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res. 2000;28:235–242.
   PubMed Web of Science ®Google Scholar
• Pruit RN, Chagot B, Cover M, Chazin WJ, Spiller B, Lacy DB. Structure–function analysis of inositol hexakisphosphate-induced autoprocessing in Clostridium difficile toxin A. J Biol Chem. 2009;284:21934–21940.
   PubMed Web of Science ®Google Scholar
• Sundaramoorthy M, Gold MH, Poulos TL. Ultrahigh resolution structure of manganese peroxidase from Phanerochaete chrysosporium implications for the catalytic mechanism. J Inorg Biochem. 2010;104:683–690.
   PubMed Web of Science ®Google Scholar
• Pilka ES, Philips C, King ONF, Guo K, Delft FV, Pike ACW, Arrowsmith CH, Weigelt J, Edwards AM, Oppermann U. Crystal structure of human β-hydroxyisobutyryl-CoA hydrolase in complex with quercetin. The Protein Data Bank. [cited 2013 Apr 2]. Available from: http://www.rcsb.org/pdb/explore/explore.do?structureId = 3BPT.
   Google Scholar
• Singer AU, Skarina T, Onopriyenko O, Edwards AM, Anderson WF, Savchenko A. Structure of IDP00107, a potential N-acetyl-gamma-glutamylphosphate reductase from Shigella flexneri. The Protein Data Bank. [cited 2013 Apr 2]. Available from: http://www.rcsb.org/pdb/explore/explore.do?structureId = 3DR3.
   Google Scholar
• Dewar MJS, Zoebisch EG, Heally EF, Stewart JJP. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc. 1985;107:3902–3909.
   Web of Science ®Google Scholar
• Doherty D. MOLSIM: molecular mechanics and dynamics simulation software – user's guide, 3.2V. Lake Forest (IL): The Chem21 Group, Inc.; 1997.
   Google Scholar
• Tokarski JS, Hopfinger AJ. Prediciton of ligand–receptor binding thermodynamics by free energy force field (FEFF) 3D-QSAR analysis: application to a set of peptidometic rennin inhibitors. J Chem Inf Comput Sci. 1997;37:792–811.
   PubMedGoogle Scholar
• Gaussian, Inc. Gaussian 03W for Windows, 6V. Pittsburgh (PA): Gaussian, Inc.; 1995–2003.
   Google Scholar
• Breneman CM, Wiberg KB. Detemining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis. J Comput Chem. 1990;11:361–373.
   Web of Science ®Google Scholar
• Connolly M. Analytical molecular surface calculation. J Appl Crystallogr. 1983;16:548–558.
   Web of Science ®Google Scholar
• Connolly M. Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983;221:709–713.
   PubMed Web of Science ®Google Scholar
• Accelrys, Inc. ViewerLite, 4.2V. San Diego (CA): Accelrys, Inc.; 2001.
   Google Scholar
• Leach AR. Molecular modelling: principles and applications. London: Prentice Hall; 2001.
   Google Scholar
• Tokarski JS, Hopfinger AJ. Constructing protein models for ligand-receptor binding thermodynamic simulations: an application to a set of peptidometic renin inhibitors. J Chem Inf Comput Sci. 1997;37:779–791.
   PubMedGoogle Scholar